Literature DB >> 15087100

Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy.

Berten P G M Ceulemans1, Lieve R F Claes, Lieven G Lagae.   

Abstract

Mutations in the alpha-subunit of the first neuronal sodium channel gene SCN1A have been described in isolated patients with severe myoclonic epilepsy in infancy or Dravet syndrome and in families with generalized epilepsy with febrile seizures plus. To find phenotype/genotype correlations, we reviewed all published cases of mutations in SCN1A in addition to four new patients reported here. A total of 60 mutations were observed. Approximately 52% (31/60) are truncating mutations correlating with de novo cases of classical Dravet syndrome in 32 of 34 (94%) patients. Missense mutations in the pore-forming part constitute 27% (16/60) and correspond to a classical type in 12 of 16 (75%) patients. Missense mutations in the voltage sensor were present in 12% (7/60) and correlate with a clinical picture ranging from febrile seizures plus to severe myoclonic epilepsy in infancy. Outside these regions missense mutations are rare and account for only 10% (6/60), corresponding mostly with febrile seizures plus. These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087100     DOI: 10.1016/j.pediatrneurol.2003.10.012

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  28 in total

Review 1.  Sodium channel mutations in epilepsy and other neurological disorders.

Authors:  Miriam H Meisler; Jennifer A Kearney
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 2.  Genetics of drug resistance in epilepsy.

Authors:  Sanjay M Sisodiya
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

3.  A plethora of SCN1A mutations: what can they tell us?

Authors:  Robyn Wallace
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

4.  Scn2a sodium channel mutation results in hyperexcitability in the hippocampus in vitro.

Authors:  Kara Buehrer Kile; Nan Tian; Dominique M Durand
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

Review 5.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

6.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Authors:  Sarah K Tate; Chantal Depondt; Sanjay M Sisodiya; Gianpiero L Cavalleri; Stephanie Schorge; Nicole Soranzo; Maria Thom; Arjune Sen; Simon D Shorvon; Josemir W Sander; Nicholas W Wood; David B Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

7.  Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy.

Authors:  John C Oakley; Franck Kalume; Frank H Yu; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

8.  SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.

Authors:  Huihui Sun; Yuehua Zhang; Jianmin Liang; Xiaoyan Liu; Xiuwei Ma; Husheng Wu; Keming Xu; Jiong Qin; Yu Qi; Xiru Wu
Journal:  J Hum Genet       Date:  2008-06-20       Impact factor: 3.172

9.  Novel mutation confirms seizure locus SCN1A is also familial hemiplegic migraine locus FHM3.

Authors:  J Jay Gargus; Anne Tournay
Journal:  Pediatr Neurol       Date:  2007-12       Impact factor: 3.372

10.  Dravet syndrome.

Authors:  Gemma Incorpora
Journal:  Ital J Pediatr       Date:  2009-09-08       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.